How well does HRT actually relieve menopause symptoms?
HRT is highly effective for the classic symptoms of menopause. A meta-analysis of 24 randomized controlled trials involving over 5,000 women found that HRT significantly reduced the Kupperman menopause index (a measure of hot flashes, sweating, and sleep problems) and improved menopause-specific quality-of-life scores [2]. In a real-world study of 809 women, the average Kupperman score dropped from 40 (severe) to 11 (mild) after 24 months of therapy [5]. Another trial of 152 women reported that adding HRT to conventional care boosted treatment effectiveness from 87% to 96% and also improved mood and sleep quality [4].
These benefits extend beyond symptom relief. The same meta-analysis showed HRT increased lumbar spine bone density by a large margin (standardized mean difference 1.52) and improved vaginal health [2]. A 24-month study confirmed that osteoporosis prevalence fell from 18% to 14% with HRT [5]. For women with severe or refractory symptoms, subcutaneous HRT implants also provide high satisfaction and good long-term control [8].
What are the main risks of HRT, and who is most vulnerable?
The most concerning risks are breast cancer and cardiovascular events, and they are not the same for every woman. A meta-analysis of four randomized trials in breast cancer survivors found that HRT increased the risk of cancer recurrence by 46% (hazard ratio 1.46), especially in women with hormone receptor-positive tumors (80% increased risk) [3]. A large population-based study from the UK (43,183 breast cancer cases) confirmed that the risk is driven mainly by synthetic progestins, not by estrogen alone or by micronized progesterone [7]. This means the type of progestogen matters greatly.
On the cardiovascular side, a nationwide U.S. analysis of 172,086 women found that HRT users had roughly 2.7 times the risk of atrial fibrillation and 2.2 times the risk of heart failure hospitalization over three years [1]. However, this study did not separate women by age or time since menopause, which are known to modify risk. Importantly, the same meta-analysis that showed symptom benefits found no increase in overall adverse events or cholesterol problems [2], and a long-term follow-up of the KEEPS trial (275 women, ~10 years) found no cognitive harm from HRT started early in menopause [6]. These mixed results underscore that risk depends on timing, formulation, and individual health.
Who should avoid HRT, and what are the safer alternatives?
HRT is generally not recommended for women with a history of hormone-sensitive breast cancer, endometrial cancer, or other gynecologic cancers. In breast cancer survivors, the risk of recurrence is clear [3]. For endometrial cancer survivors, limited evidence from a small study (33 patients) showed no recurrences with HRT, but experts advise caution and recommend it only for early-stage, low-risk cases [9][10]. Women with advanced or high-risk gynecologic cancers should avoid systemic HRT [10].
For women who cannot or choose not to take systemic HRT, several options exist. Vaginal estrogen or vaginal dehydroepiandrosterone (DHEA) can treat genitourinary symptoms without raising systemic hormone levels [10]. Ospemifene, a non-estrogen oral medication, also improves vaginal symptoms without increasing cancer recurrence risk in early studies [10]. Non-hormonal treatments like certain antidepressants, gabapentin, and lifestyle changes can help with hot flashes, though they are generally less effective than HRT [10]. The key is a shared decision-making process that weighs a woman's symptom burden, cancer history, and cardiovascular risk profile.
About These Sources
This answer is built on 10 peer-reviewed studies — published from 2021 to 2026, 6 from 2024 or later, 2 in Q1 journals, collectively cited 160 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 83 papers retrieved from a database of over 500 million.
Sources used in this answer
Abstract 4369715: Hormone Replacement Therapy and Arrhythmia Risk in Menopause: A Comprehensive Nationwide Analysis
In a large U.S. cohort of 172,086 women, HRT was associated with significantly higher risks of atrial fibrillation (HR 2.74), ventricular tachycardia (HR 2.04), and heart failure hospitalization (HR 2.19) over 3 years.
Effectiveness and safety of hormone replacement therapy in the treatment of menopausal syndrome: a meta-analysis
A meta-analysis of 24 RCTs (5,089 women) found HRT significantly improved menopause symptoms, bone density, and vaginal health without increasing overall adverse events or cholesterol levels.
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis
A meta-analysis of 4 RCTs (4,050 breast cancer survivors) found HRT increased the risk of breast cancer recurrence by 46% (HR 1.46), with a stronger effect in hormone receptor-positive disease (HR 1.8).
Effects of hormone replacement therapy on mood and sleep quality in menopausal women
In a randomized trial of 152 menopausal women, HRT plus conventional care improved menopause symptoms, mood, and sleep quality more than conventional care alone, with comparable adverse event rates.
Real-world study on the effectiveness and breast safety analysis of hormone replacement therapy during menopause
A real-world study of 809 women over 24 months showed HRT reduced osteoporosis prevalence from 18% to 14% and improved Kupperman scores from 40 to 11, with no significant changes in breast density.
Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study
The KEEPS Continuation Study (275 women, ~10-year follow-up) found no long-term cognitive harm or benefit from HRT started early in menopause, providing reassurance about neurocognitive safety.
Menopausal Hormone Therapy Formulation and Breast Cancer Risk
A UK case-control study of 43,183 breast cancer cases found that the increased breast cancer risk with HRT was driven by synthetic progestins (OR 1.28), not by estrogen alone or micronized progesterone.
Hormone replacement therapy subcutaneous implants for refractory menopause symptoms; the patient’s perspective
A survey of 119 women using HRT subcutaneous implants for refractory symptoms reported high satisfaction and good symptom control, supporting their value for difficult cases.
Profiling of menopausal symptoms and therapeutic effects of hormone replacement therapy (HRT) in endometrial cancer survivors
In a retrospective study of 33 endometrial cancer survivors, HRT improved menopausal symptoms in 96% of patients with no recurrences during a median 2.6-year follow-up.
Comment on “Hormone Replacement Therapy in Gynecologic Cancer: Oncologic Safety and Alternative Therapies”
A literature review concluded that HRT is safe for most gynecologic cancer survivors (cervical, ovarian, early-stage endometrial) but is not recommended for high-risk or advanced-stage cancers.